TURP Treatment (Transurethral Resection of Prostate) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Transurethral resection of the prostate (TURP) is the gold standard endoscopic surgical treatment for benign prostatic hyperplasia (BPH) causing significant lower urinary tract symptoms (LUTS) in men with prostate volumes of 30–80 mL. The procedure removes obstructing prostatic adenoma tissue using a resectoscope — a rigid endoscope passed through the urethra without any external incision. TURP has been performed since the 1930s, and over 400,000 procedures are performed annually in the United States alone, making it one of the most commonly performed urological operations worldwide. The procedure works by resecting the transitional zone of the prostate — the periurethral zone that expands in BPH and compresses the urethral lumen — creating a wider urethral channel that allows urine to flow freely. Traditional monopolar TURP uses high-frequency electrical current via a tungsten loop to resect prostate chips in glycine (non-conducting) irrigation fluid. Bipolar TURP — now the predominant technique — uses high-frequency current between two electrodes on the resectoscope loop in normal saline irrigation, eliminating the risk of TUR syndrome (dilutional hyponatraemia from glycine absorption) and allowing resection of larger glands with greater haemostatic control. Compared to medical management, TURP provides greater and more durable symptom relief — IPSS score improvement of 70–80% versus 30–40% with alpha-blockers — and is the definitive surgical treatment for BPH in the 30–80 mL prostate size range. For prostates over 80 mL, HoLEP (holmium laser enucleation of the prostate) or simple open prostatectomy is preferred over TURP due to lower transfusion and re-operation rates in larger glands.

TURP is indicated primarily for BPH causing clinically significant LUTS that has failed adequate medical therapy. Absolute surgical indications for TURP regardless of symptom score include: acute urinary retention refractory to medical management (one or more episodes), chronic urinary retention with residual volumes above 300 mL, recurrent urinary tract infections attributable to incomplete bladder emptying, bladder stones secondary to BPH and incomplete voiding, upper tract dilation or renal impairment from obstructive uropathy, and recurrent haematuria from prostatic vessels. Relative indications include moderate-to-severe LUTS (IPSS 8 or above) significantly affecting quality of life, maximum urinary flow rate (Qmax) persistently below 10 mL/s, and patient preference for definitive surgical treatment over long-term medical therapy. TURP is suitable for prostate volumes of approximately 30–80 mL; bilateral monopolar resection of very large glands (over 80 mL) carries higher risks of TUR syndrome, prolonged operating time, and transfusion requirement. Bladder neck contracture — a distinct condition from BPH where the bladder neck is fibrotic rather than adenomatous — can be treated by TURP-style incision (bladder neck incision, BNI) rather than resection. Primary bladder outlet obstruction from bladder neck sclerosis in younger men (non-BPH) may also respond to TURP-style incision.

Pre-TURP assessment ensures the patient is an appropriate candidate and that the risk-benefit profile supports surgery. IPSS and quality-of-life impact questionnaire quantify symptom burden. Uroflowmetry with post-void residual (PVR) by bladder ultrasound confirms obstructive pattern — low Qmax with high PVR. Prostate size is assessed by transrectal ultrasound (TRUS) or MRI — volumes over 80 mL require discussion of HoLEP or open prostatectomy as preferred alternatives. PSA measurement is mandatory to risk-stratify for prostate cancer before resecting prostate tissue. If PSA exceeds age-appropriate thresholds or PSA density is elevated, mpMRI prostate and targeted biopsy are performed before TURP. Urine culture must be sterile — bacteria must be treated with appropriate antibiotics before elective surgery to prevent post-operative urosepsis. Renal function, full blood count, and coagulation status are assessed. Antiplatelet agents (aspirin, clopidogrel) are usually withheld for 5–7 days before surgery. Patients with cardiac devices (pacemakers, ICDs) should be evaluated by the cardiologist — monopolar TURP electrical current is contraindicated with pacemakers (bipolar TURP is safer). Urodynamic studies are performed in men with impaired bladder contractility to distinguish outlet obstruction from detrusor underactivity — surgery does not benefit men whose poor voiding is due to detrusor failure rather than obstruction.

Bipolar TURP is the current standard — the resectoscope loop excises prostate chips using bipolar current in normal saline, chip by chip, creating the 'TURP channel' from bladder neck to verumontanum. Simultaneous coagulation maintains haemostasis. Operating time: 45–90 minutes depending on prostate volume (approximately 1 mL of adenoma removed per minute of TURP). A three-way urethral catheter is left for continuous bladder irrigation until haematuria clears (24–48 hours), then the catheter is removed and voiding is assessed before discharge. Holmium laser enucleation of the prostate (HoLEP) is the most effective endoscopic procedure for BPH regardless of prostate size — it enucleates the entire prostate adenoma en bloc and morcellates it intravesically. HoLEP has a higher upfront equipment cost and learning curve (30–50 procedures) but offers lower re-operation rates (2–3% vs 8–15% for TURP at 10 years), lower transfusion rates (less than 1%), and superior long-term durability, particularly for prostates over 80 mL. Photoselective vaporisation of the prostate (PVP, GreenLight laser) vaporises prostate tissue using a 532 nm laser — suitable for patients on anticoagulation (coagulation-sparing due to minimal bleeding), though tissue is destroyed (not available for histology). Aquablation (robotic water-jet ablation guided by real-time TRUS) removes prostate tissue robotically preserving the surgical capsule and ejaculatory ducts — 95% ejaculation preservation rate. Office-based alternatives (Rezum, UroLift) are for men with smaller prostates prioritising ejaculatory function and avoiding general/spinal anaesthesia.

TURP provides durable improvement in BPH symptoms: IPSS score reduction of 70–80% (from approximately 18–20 to 4–6 points), Qmax improvement from a median of 8 mL/s to 20–22 mL/s, post-void residual reduction from 150–200 mL to below 50 mL, and significant nocturia reduction. Quality-of-life scores improve substantially. The IPSS quality-of-life bother score improves from 4–5 to 1–2 in most patients. Bipolar TURP maintains equivalent efficacy to monopolar with a superior safety profile — TUR syndrome is eliminated, catheterisation time is reduced, and hospital stay averages 1–2 days. A Cochrane systematic review confirms TURP superiority over all medical therapies for objective flow rate improvement. Re-operation rate at 10 years for symptom recurrence or stricture is 8–15% — lower than for office-based procedures (20–30% at 5 years for Rezum and UroLift) and somewhat higher than for HoLEP. TURP resection tissue is available for histopathology — incidental prostate cancer is found in resection chips in 8–10% of cases, allowing early cancer detection.

TUR syndrome — dilutional hyponatraemia from absorption of hypotonic glycine irrigation into the bloodstream — is the classic historical complication of monopolar TURP, presenting with nausea, confusion, bradycardia, and seizures from severe hyponatraemia. This is effectively eliminated by bipolar TURP in normal saline. Retrograde ejaculation (semen refluxes into the bladder during orgasm rather than being expelled) is the most common side effect, occurring in 80–90% of men after TURP — it is painless but causes anejaculation and is an important discussion point for men who wish to preserve fertility or ejaculatory sensation. Erectile dysfunction: a new onset in 5–10% of patients — TURP generally does not damage the cavernous nerves, but intravascular pressure changes and thermal effects may occasionally impair erection. Urinary incontinence: stress incontinence affects 1–3% of patients and is usually transient (weeks to months), resolving with pelvic floor physiotherapy. Permanent incontinence from sphincter damage is rare (less than 0.5%). Urethral stricture at the external meatus, bulbar urethra, or bladder neck contracture (anastomotic stricture) develops in 4–10% and requires endoscopic dilation or urethrotomy. Significant intraoperative haemorrhage requiring blood transfusion: 1–2% with bipolar TURP. Clot retention in the immediate post-operative period requiring manual bladder washout or catheter replacement: 2–5%. Urinary tract infection: 5–10% despite routine prophylaxis. Transient urinary urgency and frequency during tissue healing: common, resolving within 4–6 weeks.

After TURP, the urethral catheter is removed when haematuria clears (typically 24–48 hours post-operatively) and voiding is assessed. Most men are discharged on day 1–2. A trial without catheter (TWOC) confirms adequate voiding — post-void residual ultrasound below 100 mL confirms satisfactory emptying. Haematuria improving daily is expected; vigorous activity, sexual intercourse, and heavy lifting are restricted for 4–6 weeks to reduce late bleeding risk. Frequency, urgency, and dysuria during the healing phase are normal, managed with anticholinergics (solifenacin, oxybutynin) if persistent. Clinical review at 4–6 weeks with IPSS questionnaire, uroflowmetry, and PVR confirms treatment response. Qmax above 15 mL/s and IPSS improvement of 50%+ confirm a satisfactory outcome. TURP resection tissue histopathology results are reviewed at the 6-week appointment — prostate cancer found incidentally in chips (pT1a disease, less than 5% of chips) may require surveillance or treatment discussion. PSA falls by 50–70% within 3–6 months after TURP — subsequent PSA monitoring screens for prostate cancer in the residual peripheral zone tissue (TURP does not remove all prostate tissue, only the adenoma). Annual uroflowmetry detects symptom recurrence from regrowth of residual adenoma tissue, typically occurring 8–10 years after TURP.

TURP is significantly more affordable than most urological oncological procedures, making it accessible in many healthcare systems. Bipolar TURP: India USD 1,500–4,000 (including anaesthesia, 1–2 night hospital stay); Thailand USD 3,000–7,000; Turkey USD 2,000–5,000; Mexico USD 3,000–6,000; USA USD 10,000–20,000 (hospital and anaesthesia account for 70–80% of US cost); UK NHS: free at point of care; UK private: GBP 4,000–8,000. Monopolar TURP (older technique, lower equipment cost): India USD 1,000–2,500. PVP (GreenLight laser): India USD 2,000–5,000; USA USD 12,000–25,000. HoLEP: India USD 2,500–6,000; USA USD 12,000–28,000 (higher HoLEP cost versus TURP reflects laser equipment and longer learning curve). Preoperative assessment (IPSS, uroflowmetry, TRUS, PSA, anaesthetic assessment): India USD 100–300; USA USD 500–2,000. Post-operative review and uroflowmetry (4–6 weeks): India USD 50–100; USA USD 200–500. Medical tourism to India for TURP offers savings of 70–85% versus US costs, with equivalent bipolar TURP technique at major urological centres.

Medical management with alpha-blockers (tamsulosin, alfuzosin) and/or 5-ARIs (finasteride, dutasteride) effectively controls moderate LUTS in 60–70% of men who are not ideal surgical candidates or who prefer to avoid surgery. Combination therapy is superior to monotherapy for large prostates. HoLEP (holmium laser enucleation) is the recommended alternative to TURP at EAU guideline level — it enucleates the complete adenoma regardless of prostate size, offers lower re-operation rates and transfusion risk, and is the preferred procedure for prostates over 80 mL or in patients on anticoagulation. Photoselective vaporisation of the prostate (PVP, GreenLight 180W XPS) is an effective alternative for men on anticoagulation where haemostasis is paramount — the laser vaporises tissue with very low intraoperative bleeding. Simple open prostatectomy (Millin or Freyer technique) is reserved for very large prostates (over 150 mL) or when concurrent bladder pathology (large bladder stones, diverticulum) requires open access. Office-based procedures — Rezum (water vapour therapy), UroLift (prostatic urethral lift implants) — are minimally invasive alternatives for men with smaller prostates (30–80 mL) who prioritise ejaculatory function preservation and avoidance of general anaesthesia, accepting lower durability (20–30% need retreatment at 5 years). Prostate artery embolisation (PAE) is an IR procedure suitable for high surgical risk men.